- AtriCure's CTO CTO--sold shares at $55 (52-week high) under a pre-planned 10b5-1 trading program, retaining 80% ownership. - The company turned profitable in 2026 with 77% gross margins, $9M net ...

Image source: The Motley Fool. MNTN(NYSE:MNTN) delivered double-digit top-line growth and nearly doubled adjusted EBITDA, highlighting broad-based strength in performance TV software and targeted new ...

Good afternoon, and welcome to AtriCure's First Quarter 2026 Earnings Conference Call. This call is being recorded for replay purposes. [Operator Instructions] I would now like to turn the call over ...

Worldwide revenue for the first quarter 2026 was $141.2 million, an increase of 14.3% over first quarter 2025 revenue (12.8% on a constant currency basis). U.S. revenue was $116.2 million, an increase ...

Mason, Ohio-based AtriCure, a specialist in surgical treatments and therapies for atrial fibrillation, left atrial appendage management, and post-operative pain management, saw substantial revenue ...

Introduction: Intraoperative transesophageal echocardiography (TEE) is essential to guide left atrial appendage (LAA) closure and exclusion. Despite a significant learning curve, TEE can be performed ...

Trial will evaluate the safety and effectiveness of the AtriCure Isolator® Synergy™ EnCompass® clamp and AtriClip® Left Atrial Appendage Exclusion System to reduce the occurrence of new-onset atrial ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today ...

Medtronic added Penditure to its portfolio through the acquisition of Syntheon. The company launched the device in the U.S. shortly after inking the takeover. This week, Medtronic said it has sold ...